

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number		10775883
Filing Date		2004-02-04
First Named Inventor	Robert Eugene HORMANN	
Art Unit	1883	
Examiner Name	Brian J. DAVIS	
Attorney Docket Number	A9536	

U.S. PATENTS[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5530028		1996-06-25	ROHM and HAAS COMPANY	
	2	5880333		1999-03-09	NORVARTIS FINANCE CORP	
	3	6265173		2001-07-24	SALK INST FOR BIOLOGICAL STUDIES	
	4	6300488		2001-10-09	SALK INST FOR BIOLOGICAL STUDIES	
	5	4954655		1990-09-04	ROHM and HAAS COMPANY	
	6	4985461		1991-01-15	ROHM and HAAS COMPANY	
	7	6013836		2000-01-11	ROHM and HAAS COMPANY	
	8	6147282		2000-11-14	NOVARTIS FINANCE CORP Goff et al.	

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775883
Filing Date	2004-02-04
First Named Inventor	Robert Eugene HORMANN
Art Unit	1883
Examiner Name	Brian J. DAVIS
Attorney Docket Number	A9536

9	6245531		2001-06-12	BOARD TRUSTEES OF LELAND STANFORD UNIVERSITY	
10	6258603		2001-07-10	R0HM and HAAS COMPANY	
11	5424333		1995-06-13	R0HM and HAAS COMPANY	
12	5358966		1994-10-25	R0HM and HAAS COMPANY	
13	5075471		1991-12-24	R0HM and HAAS COMPANY	
14	4950666		1990-08-21	FMC Corporation	
15	4906280		1990-03-06	PENNWALT CORPORATION	
16	4814349		1989-03-21	AMERICAN CYANAMID COMPANY	
17	5482962		1996-01-09	R0HM and HAAS COMPANY	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
----------------------	------------	--------------------	---------------------------	---------------------	--	--

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10775883
Filing Date	2004-02-04
First Named Inventor	Robert Eugene HORMANN
Art Unit	1883
Examiner Name	Brian J. DAVIS
Attorney Docket Number	A9536

1						
---	--	--	--	--	--	--

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0965644	EP		1999-12-22	ROHM & HAAS		<input type="checkbox"/>
	2	2000026423	JP		2000-01-25	OTSUKA CHEM CO LTD		<input checked="" type="checkbox"/>
	3	09100262	JP		1997-04-15	ROHM & HAAS CO		<input checked="" type="checkbox"/>
	4	08231528	JP		1996-10-09	NIPPON KAYAKU CO LTD & SANKYO CO LTD		<input checked="" type="checkbox"/>
	5	08231529	JP		1996-09-10	NIPPON KAYAKU CO LTD & SANKYO CO LTD		<input checked="" type="checkbox"/>
	6	06184076	JP		1994-07-05	NIPPON KAYAKU CO LTD & SANKYO CO LTD	ABSTRACT	<input type="checkbox"/>
	7	06172342	JP		1994-06-21	NIPPON KAYAKU CO LTD & SANKYO CO LTD		<input checked="" type="checkbox"/>
	8	05039252	JP		1993-02-19	NIPPON KAYAKU CO LTD		<input checked="" type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775883
Filing Date	2004-02-04
First Named Inventor	Robert Eugene HORMANN
Art Unit	1883
Examiner Name	Brian J. DAVIS
Attorney Docket Number	A9536

9	04235177	JP		1992-08-24	NIPPON KAYAKU CO LTD	ABSTRACT	<input type="checkbox"/>
10	04089471	JP		1992-03-23	NIPPON KAYAKU CO LTD	ABSTRACT	<input type="checkbox"/>
11	03145447	JP		1991-06-20	NISSAN CHEM IND LTD	ABSTRACT	<input type="checkbox"/>
12	03141245	JP		1991-06-17	ISHIHARA SANGYO KAISHA LTD	ABSTRACT	<input type="checkbox"/>
13	02207066	JP		1990-08-16	ISHIHARA SANGYO KAISHA LTD	ABSTRACT	<input type="checkbox"/>
14	0236618	EP		1987-09-16			<input type="checkbox"/>
15	1313276	CN		2001-09-19		ABSTRACT	<input type="checkbox"/>
16	1245638	CN		2000-03-01		ABSTRACT	<input type="checkbox"/>
17	0228564	EP		1992-01-29			<input type="checkbox"/>
18	19837620	DE		1999-02-25	NOVARTIS AG	ABSTRACT	<input type="checkbox"/>
19	0639559	EP		1995-02-22	ROHM AND HAAS CO		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10775883
Filing Date		2004-02-04
First Named Inventor	Robert Eugene HORMANN	
Art Unit	1883	
Examiner Name	Brian J. DAVIS	
Attorney Docket Number	A9536	

20	2103110	CA		1994-05-24			<input type="checkbox"/>
21	0496342	EP		1996-11-27			<input type="checkbox"/>
22	0461809	EP		1994-12-07			<input type="checkbox"/>
23	0361645	EP		1990-04-04			<input type="checkbox"/>
24	2231268	GB		1990-11-14	ROHM AND HAAS CO		<input type="checkbox"/>
25	0395581	EP		1990-10-31			<input type="checkbox"/>
26	0347216	EP		1989-12-20			<input type="checkbox"/>
27	0339854	EP		1989-11-02			<input type="checkbox"/>
28	0286746	EP		1988-10-19			<input type="checkbox"/>
29	62209053	JP		1987-09-14		CORRESPONDS TO ABSTRACT EP0232075	<input type="checkbox"/>
30	62293150	JP		1987-11-16		CORRESPONDS TO ABSTRACT EP0245950	<input type="checkbox"/>

10775883

2004-02-04

Robert Eugene HORMANN

1883

Brian J. DAVIS

A9536

31 0253468 EP 1991-11-06

32 0234944 EP 1987-02-27

Add

Remove

- 1 Nakagawa, Yoshiaki et al., Quantitative structure-activity studies of insect growth regulators. XI. Stimulation and inhibition of N-acetylglucosamine incorporation in a cultured integument system by substituted N-tert-butyl-N,N'-dibenzoylhydrazines. *Pesticide Science* (1995), 43(4), 339-45.
- 2 Nakagawa, Yoshiaki et al., Quantitative structure-activity relationships and designed synthesis of larvicidal N,N'-dibenzoyl-N-tert-butylhydrazines against *Chila suppressalis*. *Pesticide Science* (1995), 44(1), 102-5.
- 3 Le, D. P. et al., RH-2485 A new selective insecticide for caterpillar control. Brighton Crop Protection Conference--Pests and Diseases (1996), (Vol. 2), 481-486.
- 4 Carlson, Glenn R. et al., The chemical and biological properties of methoxyfenozide, a new insecticidal ecdysteroid agonist. *Pest Management Science* (2001), 57(2), 115-119.
- 5

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775883
Filing Date	2004-02-04
First Named Inventor	Robert Eugene HORMANN
Art Unit	1883
Examiner Name	Brian J. DAVIS
Attorney Docket Number	A9536

8	Nie, Kaisheng et al., New type of insect growth regulator-chromafenozide. Nongyao (2001), 40(2), 42-43.	<input type="checkbox"/>
9	Cao, S. et al., N'-tert-butyl-N'-aroyl-N-(alkoxycarbonylmethyl)-N-aroylhydrazines, a novel nonsteroidal ecdysone agonist: syntheses, insecticidal activity, conformational, and crystal structure analysis. Canadian Journal of Chemistry (2001), 79(3), 272-278.	<input type="checkbox"/>
10	Sawada, Yoshihiro et al., Synthesis and insecticidal activity of 3,5-dimethylbenzoyl moiety modified analogues of N-tert-butyl-N'-(4-ethylbenzoyl)-3,5-dimethylbenzohydrazide. Nippon Noyaku Gakkaishi (2002), 27(4), 365-373.	<input type="checkbox"/>
11	Nakagawa, Yoshiaki et al., Quantitative structure-activity studies of insect growth regulators: XIX. Effects of substituents on the aromatic moiety of dibenzoylhydrazines on larvicidal activity against the beet armyworm Spodoptera exigua. Pest Management Science (2002), 58(2), 131-138.	<input type="checkbox"/>
12	No, D. et al., "Ecdysone-Inducible Gene Expression in Mammalian Cells and Transgenic Mice," Proc. Natl. Acad. Sci. USA, vol. 93, pp. 3346-3351, 1996.	<input type="checkbox"/>
13	Zou, Xia-Juan et al. Synthesis of N-benzoyl-N-tert-butyl-N'-[(1,4-dihydro-6-methyl-4-oxo-1-phenyl-3-pyridazinyl)carbonyl]hydrazines. Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2003), 42B(10), 2608-2611.	<input type="checkbox"/>
14	Lynn M. RIDDIFORD et al., "Ecdysone Receptors and Their Biological Actions", Vitamins and Hormones, 2000, 60:1-73.	<input type="checkbox"/>
15	Karen S. CHRISTOPHERSON et al., "Ecdysteroid-dependent regulation of genes in mammalian cells by a Drosophila ecdysone receptor and chimeric transactivators", Proc. Natl. Acad. Sci. U.S.A., 1992, 89: 6314-6318.	<input type="checkbox"/>
16	Suhr et al., "High level transactivation by a modified Bombyx ecdysone receptor in mammalian cells without exogenous retinoid X receptor" PNAS, 1998;95: 7999-8004	<input type="checkbox"/>
17	Kakizawa T et al., "Ligand-dependent Heterodimerization of Thyroid Hormone Receptor and Retinoid X Receptor" 1997, JBC, 272: 38; 23799-23804	<input type="checkbox"/>
18	Wing, Keith D. et al., RH 5849, a nonsteroidal ecdysone agonist: effects on a Drosophila cell line. Science (Washington, DC, United States) (1988), 241(4864), 467-9.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775883
Filing Date	2004-02-04
First Named Inventor	Robert Eugene HORMANN
Art Unit	1883
Examiner Name	Brian J. DAVIS
Attorney Docket Number	A9536

19	Sawada, Yoshihiro et al., Synthesis and insecticidal activity of benzoheterocyclic analogues of N'-benzoyl-N-(tert-butyl)benzohydrazide: part 2. Introduction of substituents on the benzene rings of the benzoheterocycle moiety. Pest Management Science (2003), 59(1), 36-48.	<input type="checkbox"/>
20	Sawada, Yoshihiro et al., Synthesis and insecticidal activity of benzoheterocyclic analogues of N'-benzoyl-N-(tert-butyl)benzohydrazide. Part 3. Modification of N-tert-butylhydrazine moiety. Pest Management Science (2003), 59(1), 49-57.	<input type="checkbox"/>
21	Koelle MR et al., The Drosophila EcR gene encodes an ecdysone receptor, a new member of the steroid receptor superfamily, Cell, 1991, 67: 59-77	<input type="checkbox"/>
22	BELSHAW et al., Rational design of orthogonal receptor-ligand combinations. Angewandte Chemie, International Edition in English (1995), 34(19), 2129-32.	<input type="checkbox"/>
23	PIERCE et al., Computational binding studies of orthogonal cyclosporin-cyclophilin pairs. Angewandte Chemie, International Edition in English (1997), 36(13/14), 1466-1469.	<input type="checkbox"/>
24	PEET et al., Engineering Novel Specificities for Ligand-Activated Transcription in the Nuclear Hormone Receptor RXR. Chemistry & Biology, 1998, 5, 1, 13-21.	<input type="checkbox"/>
25	HOLT et al., Functional Expression of Exogenous Proteins in Mammalian Sensory Hair Cells Infected with Adenoviral Vectors. J Neurophysiol. (1999), 81(4), 1881-8.	<input type="checkbox"/>
26	Sawada, Yoshihiro et al., Synthesis and insecticidal activity of benzoheterocyclic analogues of N'-benzoyl-N-(tert-butyl)benzohydrazide. Part 1. Design of benzoheterocyclic analogues. Pest Management Science (2003), 59(1), 25-35.	<input type="checkbox"/>
27	Hoppe et al., Adenovirus-Mediated Inducible Gene Expression in Vivo by a Hybrid Ecdysone Receptor. Molecular Therapy (2000) 1(2), 159-164.	<input type="checkbox"/>
28	Zhang, Xiangning et al., Study on synthesis and bioactivity of new diacylhydrazine IGR JS118. Nongyao (2003), 42(12), 18-20	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775883
Filing Date	2004-02-04
First Named Inventor	Robert Eugene HORMANN
Art Unit	1883
Examiner Name	Brian J. DAVIS
Attorney Docket Number	A9536

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10775883
Filing Date	2004-02-04
First Named Inventor	Robert Eugene HORMANN
Art Unit	1883
Examiner Name	Brian J. DAVIS
Attorney Docket Number	A9536

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Todd B. Buck/	Date (YYYY-MM-DD)	2007-06-14
Name/Print	Todd B. Buck	Registration Number	48,574

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.